Trial Profile

A Phase 2 clinical study of ADX-629 in patients with COVID-19-associated respiratory compromise

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 10 Aug 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Aug 2020 According to a Aldeyra Therapeutics media release, the company has completed an Investigational New Drug (IND) submission under the FDA's Coronavirus Accelerated Treatment Program to initiate this Phase 2 clinical trial of ADX-629 in patients with COVID-19.
07 May 2020 According to a Aldeyra Therapeutics media release, this clinical trial, contingent on FDA review of information submitted via the Coronavirus Treatment Acceleration Program (CTAP), is expected to begin in the third quarter of 2020.
22 Apr 2020 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com